Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations–a registry based analysis
Middeke JM, Teipel R, Roellig C, Stasik S, Zebisch A, Sill H, Kramer M, Scholl S, Hochhaus A, Jost E, Bruemmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, Parmentier S, Schaich M, Burchert A, Neubauer A, Schliemann C, Berdel WE, Sockel K, Stoelzel F, Platzbecker U, Ehninger G, Bornhaeuser M, Schetelig J, Thiede C (2021)
Publication Type: Journal article
Publication year: 2021
Journal
Book Volume: 62
Pages Range: 1432-1440
Journal Issue: 6
DOI: 10.1080/10428194.2020.1864354
Abstract
We performed a registry-based analysis of 311 AML patients treated with decitabine in a standard of care setting to assess response and survival data with a distinct focus on the impact of the TP53 mutation status. Median age was 73 years. 172 patients received decitabine first-line and 139 in r/r disease. The ORR (whole cohort) was 30% with a median overall survival of 4.7 months. First-line patients achieved better responses than r/r-patients (ORR: 38% vs. 21%) resulting in a median OS of 5.8 months vs. 3.9 months. NGS based mutation analysis was performed in 180 patients. 20 patients (11%) harbored a TP53 mutation. Response rates and survival did not differ significantly between TP53 mutated patients and wild-type patients. This analysis of a large cohort of AML patients provides response rates and OS data after decitabine treatment. Interestingly, outcome was not negatively influenced by a TP53 mutation.
Involved external institutions
Technische Universität Dresden
Germany (DE)
Rems-Murr-Kliniken
Germany (DE)
Universitätsklinikum Münster
Germany (DE)
Universitätsklinikum Jena
Germany (DE)
Universitätsklinikum Aachen (UKA)
Germany (DE)
St. Marien-Krankenhaus
Germany (DE)
Goethe-Universität Frankfurt am Main
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
Universitätsklinikum Leipzig
Germany (DE)
Germany (DE)
Rems-Murr-Kliniken
Germany (DE)
Universitätsklinikum Münster
Germany (DE)
Universitätsklinikum Jena
Germany (DE)
Universitätsklinikum Aachen (UKA)
Germany (DE)
St. Marien-Krankenhaus
Germany (DE)
Goethe-Universität Frankfurt am Main
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
Universitätsklinikum Leipzig
Germany (DE)
How to cite
APA:
Middeke, J.M., Teipel, R., Roellig, C., Stasik, S., Zebisch, A., Sill, H.,... Thiede, C. (2021). Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations–a registry based analysis. Leukemia & Lymphoma, 62(6), 1432-1440. https://doi.org/10.1080/10428194.2020.1864354
MLA:
Middeke, Jan M., et al. "Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations–a registry based analysis." Leukemia & Lymphoma 62.6 (2021): 1432-1440.
BibTeX: Download